Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 West 4th Ave, Vancouver, Canada

JoeTheMiner Nov. 22 at 12:32 AM

$GUTS imagine having same watchers as $ABCL or $PFE

0 · Reply

HedgeAlerts Nov. 21 at 11:05 PM

Hedge Alert Live - Protect Your Portfolio Contract: $ABCL $3.00 Put · DEC 19, 2025 Exp Entry Price: $0.20 - $0.25 Exit Price Target: $0.45 Profit Margin: +127% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

PolarBear1 Nov. 21 at 10:18 PM

$ABCL This update just yesterday…..note study completion date expected 02-2027. Dr Hanson said “this Phase 1 trial is designed to test efficacy”……we should see initial results in Q3/26.

0 · Reply

Stocktradesmoon Nov. 21 at 9:31 PM

$ABCL $ABCL is the $PLTR of Biotech $ABCL has invested heavily in a proprietary, full-stack AI platform for antibody discovery Their software for antibody discovery is in a class of its own and eventually the biotech industry will have to rely on ABCL's software to achieve success.

0 · Reply

Stocktradesmoon Nov. 21 at 8:14 PM

$ABCL Carl Hansen at Jeffries Global Health Conference: “The market won’t value [partnerships royalties] until you generate cash flow. It is part of the business and is something we hold as a valuable asset & will increasingly be recognized through time.” $ABCL

2 · Reply

JBurckhardt Nov. 21 at 7:22 PM

$ABCL in 2021 Tachyon (Founded by Stephen Quake) and AbCellera entered a collaboration involving the discovery and development of a therapeutic antibody targeting LEFTY1. Tachyon brings the target biology and disease context, while AbCellera finds the actual antibody candidates. AbCellera is eligible to receive milestone payments and royalties on products that are derived from its antibody discovery program, and has the option to invest in preclinical and clinical development in exchange for an increased share of product sales.

1 · Reply

Kaykay610 Nov. 21 at 5:41 PM

$ABCL am i the only one that realized that Stephen Quake founded tachyon and Abcellera's discovered drug tach204 has beeStephen quakesn removed from tachyon's pipeline and Stephen Quake has been added to the board.

1 · Reply

Ed_Ng Nov. 21 at 5:01 PM

$ABCL this is nice. I'm always right. If it goes above 6$ again. I will short again. If it goes to 2$, I take the rest of 50% profit. Easy trade on this POS

0 · Reply

TheDrunkTrader69 Nov. 21 at 4:13 PM

$ABCL Im buying ever opportunity downn here

0 · Reply

Stocktradesmoon Nov. 21 at 4:06 PM

$ABCL If you're not buying here This game is not for you.

0 · Reply

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 7, 2025, 7:16 PM EST - 14 days ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 15 days ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 6 weeks ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 6, 2025, 7:35 AM EDT - 6 weeks ago

AbCellera Biologics: Entering Growth Phase After A Pause

Sep 29, 2025, 4:05 PM EDT - 7 weeks ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 2 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 3 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 7:48 PM EDT - 3 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 3 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 6 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 6 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 6 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 7 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 10:33 PM EDT - 7 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 7 months ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 7 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 8 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 11:26 PM EST - 9 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 10 months ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 11 months ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 23, 2024, 4:39 PM EST - 11 months ago

AbCellera Biologics: Still A Concept Stock

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 8, 2024, 12:05 PM EDT - 1 year ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 19, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 1 year ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

JoeTheMiner Nov. 22 at 12:32 AM

$GUTS imagine having same watchers as $ABCL or $PFE

0 · Reply

HedgeAlerts Nov. 21 at 11:05 PM

0 · Reply

PolarBear1 Nov. 21 at 10:18 PM

$ABCL This update just yesterday…..note study completion date expected 02-2027. Dr Hanson said “this Phase 1 trial is designed to test efficacy”……we should see initial results in Q3/26.

0 · Reply

Stocktradesmoon Nov. 21 at 9:31 PM

0 · Reply

Stocktradesmoon Nov. 21 at 8:14 PM

2 · Reply

JBurckhardt Nov. 21 at 7:22 PM

1 · Reply

Kaykay610 Nov. 21 at 5:41 PM

1 · Reply

Ed_Ng Nov. 21 at 5:01 PM

$ABCL this is nice. I'm always right. If it goes above 6$ again. I will short again. If it goes to 2$, I take the rest of 50% profit. Easy trade on this POS

0 · Reply

TheDrunkTrader69 Nov. 21 at 4:13 PM

$ABCL Im buying ever opportunity downn here

0 · Reply

Stocktradesmoon Nov. 21 at 4:06 PM

$ABCL If you're not buying here This game is not for you.

0 · Reply

Stocktradesmoon Nov. 21 at 3:45 PM

$ABCL

1 · Reply

Targhee Nov. 21 at 3:39 PM

$ABCL No Bueno!!

0 · Reply

Ed_Ng Nov. 21 at 3:24 PM

$ABCL free fall. I took 50% of profit from here.

0 · Reply

UncleTomFlorida Nov. 21 at 1:47 PM

$PLTR $NVDA $HOOD $ABCL $ACHR These stocks form the core of my long term portfolio. $ABCL $ACHR are speculative. The others show significant profits that shelter any short term dips. I am looking for all of these to triple in value over the next three years, short sellers , naysayers & fools notwithstanding.

1 · Reply

Stocktradesmoon Nov. 21 at 1:41 PM

$ABCL "Shots on Goal" Creates Optionality for $ABCL A little while back I wrote a deep dive on Abdera Therapeutics, one of AbCellera’s earliest ADC partners. Since then, I’ve been digging further into the structure of that partnership and I realized something that I don’t think the market fully appreciates: Abdera’s entire discovered pipeline is being built on AbCellera’s antibody discovery platform. Not one program. Not “some” programs. Their whole discovery engine is powered by ABCL. This matters way more than people realize. What this actually means Because Abdera uses ABCL’s platform for every antibody entering their pipeline: Every candidate they advance comes with downstream economics for AbCellera This includes milestones and royalties on any program that reaches the market Abdera isn’t a tiny biotech with one asset. They have a multi-asset ADC platform targeting solid tumors, and they’re pushing forward aggressively

0 · Reply

Stocktradesmoon Nov. 21 at 1:41 PM

$ABCL Simply put, if Abdera hits, AbCellera gets paid. If Abdera hits multiple times, AbCellera gets paid multiple times. This is a real, tangible example of the “shots on goal” model that many people assume is theoretical or far in the future. It’s happening right now, with a partner that has serious scientific traction. And I know Abdera has their own plaform, but I think its important to distinguish what each does. AbCellera’s platform: Used to discover and optimize antibodies. Think of it as finding the best antibodies with high specificity and good drug properties. Abdera’s ROVEr™ platform: Used to turn those antibodies into radiopharmaceuticals. It attaches radioactive isotopes, tunes how the drug behaves in the body, and makes it effective and safe for cancer therapy.

0 · Reply

Stocktradesmoon Nov. 21 at 1:40 PM

$ABCL So, they compliment each other. Why this matters beyond just focusing on ABCL’s internal pipeline There’s a lot of focus on AbCellera’s internal programs (which are exciting), but I think the external pipeline is being overlooked to an extreme degree. Abdera is evidence that: ABCL’s platform is valuable enough for companies to build entire pipelines on top of it ABCL gets economic exposure without paying for clinical development, manufacturing, or commercialization ABCL’s “discovery-as-a-service” model scales dramatically if even a handful of partners behave like

0 · Reply

Stocktradesmoon Nov. 21 at 1:40 PM

$ABCL Think of Abdera as a leveraged call option on AbCellera’s tech except this one isn’t hypothetical. It’s already in motion. And why its important is because you can see beyond just the few internal assets they are developing. AbCellera ABCL575 - Phase 1 ABCL635 - Phase 1 ABCL688 - IND Enabling 4th Target announced soon Abdera ABD-147 (DLL3) – already in Phase 1, Fast Track designation ABD-320 (5T4) – in lead optimization ABD-003 – undisclosed target ABD-004 – undisclosed ABD-005 – undisclosed ABD-006 – undisclosed I think its important to have visibility into the other pipelines that are ABCL-enabled to get a better picture of how the risk is actually mitigated.

0 · Reply

Stocktradesmoon Nov. 21 at 1:39 PM

$ABCL Why Abdera specifically is interesting They’re working on radioconjugates, one of the fastest-moving spaces in oncology Early preclinical data has been strong enough that they’ve rapidly expanded their program list Their pipeline hits multiple tumor targets meaning multiple royalty-bearing shots on goal for ABCL And unlike some partnerships where ABCL only contributed discovery on one asset, here they’re effectively supplying the antibodies that power the entire company. TLDR If Abdera gets even one program approved, ABCL gets royalties. If Abdera becomes the next big radioconjugate player, ABCL becomes a quiet but powerful royalty machine sitting behind it. People often talk about ABCL optionality as if it’s 2035 fantasy. But here’s a real example today. A partner whose entire science stack depends on ABCL’s core technology. And the market, for now, is treating that as worth… basically zero.

0 · Reply

Stocktradesmoon Nov. 21 at 11:54 AM

$ABCL The final shakeout. Next week will be MONUMENTAL.

1 · Reply

ShadowBanningIsBad Nov. 21 at 5:49 AM

$ABCL 6 months later no where near 100. Hmm.

0 · Reply

Stocktradesmoon Nov. 20 at 11:51 PM

$ABCL 🧬 $ABCL — Jefferies Conference: Carl Hansen Just Defined the Entire 2026 Playbook AbCellera’s CEO Carl Hansen spoke at the Jefferies Global Healthcare Conference, and the tone was the clearest and most confident we’ve heard so far. If you’re following the platform → pipeline → clinical → royalty thesis, this was an important update. Here are the key points: ⸻ 1️⃣ ABCL635 — Phase 1 in 2026 is basically a Phase 2 Hansen said: “That study is designed essentially like a phase 2.” “If all goes as we hope, we will know whether or not we have a drug.” (Readout expected Q3 2026) This is unusually direct. Most Phase 1 studies don’t show real efficacy. ABCL635 will — by design. This turns Q3 2026 into the first major clinical catalyst in AbCellera’s history. If the data hit → ABCL moves from “platform company” to validated drug creator. ⸻

2 · Reply

Market Cap	1.08B
Revenue (ttm)	28.83M
Net Income (ttm)	-162.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-564.90%
Debt to Equity Ratio	0.00

Volume	3,490,000
Avg Vol	5,416,540
Day's Range	N/A - N/A
Shares Out	299.34M
Stochastic %K	3%
Beta	0.70
Analysts	Strong Sell
Price Target	$9.14